Gustav Smith

University of Gothenburg

Key publications

Molecular Epidemiology of Heart Failure.
JACC: Basic to Translational Science 2017

Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure.
Nature Communications 2020

Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function.
Journal of Clinical Investigation 2017

Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure.
Plos Genetics 2016

Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis.
Journal of the American Medical Association (JAMA) 2014

Genetic associations with valvular calcification and aortic stenosis.
New England Journal of Medicine 2013

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.
The Lancet 2015

Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.
Circulation (an American Heart Association Journal) 2017

Profiling of the plasma proteome across different stages of human heart failure.
Nature Communications 2019

Assessment of Conventional Cardiovascular Risk Factors and Multiple Biomarkers for the Prediction of Incident Heart Failure and Atrial Fibrillation.
Journal of the American College of Cardiology 2010

Heart disease is the leading cause of death globally, but the spectrum of heart disease varies both regionally and over time. My research group studies epidemiological patterns and molecular mechanisms for heart disease incidence and their common end-stage heart failure, in which the heart is unable to maintain the output of blood required by other tissues and intracardiac pressure increases.

We are currently particularly interested in:

  • Population genetics and genetic contributions to heart disease
  • Application of genetic tools to infer causal relations of risk factors with heart disease (‘mendelian randomization’)
  • Downstream effects of genetic variants and epigenetic modifications in heart tissues
  • Plasma profiling of metabolites and proteins to guide individually tailored prevention and therapy

Last updated: 2023-04-19

Content Responsible: Hampus Persson(